New in CLL

♥ Donate

person Sign In / Create Account

Home

All Categories

New in CLL

Read about new FDA approvals, important trial results, and other advances in CLL.

ASH 2022: Acalabrutinib vs Ibrutinib for CLL Treatment

March 08, 2023

The data showed that more CLL patients were able to take acalabrutinib for a longer period of time than those taking ibrutinib.

CLL Patients - What is CAR T-Cell Therapy?

March 02, 2023

CAR T-cell therapy is a type of immunotherapy that helps patients’ T-cells become efficient at destroying the cancer. For some CLL patients, it has cured...

ASH 2022: CAR T-cell Therapy Emerging as a Promising Treatment for Relapsed/Refractory and High-risk CLL

March 01, 2023

CAR T-cell therapy has shown promising data to effectively treat relapsed/refractory and high-risk CLL patients. Doctor Lydia Scarfò, MD presented recent data…

ASH 2022: CLL Patients' Treatment Options if Non-Covalent BTK Inhibitors Aren't Working

February 08, 2023

There is an unmet need for high-risk CLL patients that have tried covalent followed by non-covalent BTK inhibitors and become resistant. Data gathered from...

Zanubrutinib (Brukinsa) Now FDA Approved for CLL

January 27, 2023

Zanubrutinib an effective BTK inhibitor has been approved by the FDA to treat CLL and SLL.

ASH 2022: Zanubrutinib More Effective than Ibrutinib for Relapsed or Refractory CLL

January 06, 2023

Zanubrutinib more effective than ibrutinib for relapsed/refractory CLL patients in cancer reduction, stopping cancer progression, and has fewer side effects